A recent study identified increased expression of RET in breast cancer brain metastases (BCBM) relative to matched primary breast tumors, and that treatment of these BCBM tissues with MKI cabozantinib reduces RET activation, inhibits BCBM growth, and concurrently induces apoptosis (164). The gene discussed is RET; the disease is breast carcinoma.